Hong Kong Pharmaceuticals & Healthcare Report Q1 2015 - New Market Research Report

Although the ongoing political uncertainty will affect business environment, we highlight that Hong Kong will remain as an attractive market for pharmaceutical companies over the longer term owing to rising healthcare demands from its ageing population.

Headline Expenditure Projections

* Pharmaceuticals : HKD11.24bn (USD1.45bn) in 2013 to HKD12.12bn (USD1.55bn) in 2014; +7.4% in local currency terms and 7.2% in US dollar terms. Forecast unchanged from Q414.
* Healthcare: HKD122.00bn (USD15.73bn) in 2013 to HKD130.60bn (USD16.81bn) in 2014; +7.0% in local currency terms and 6.9% US dollar terms. Forecast broadly in line with Q414.

Risk/Reward Ratings

Hong Kong's Pharmaceutical Risk/Reward Rating (RRR) score for Q414 is 64.6 out of 100 in our newly improved RRR system. The country scores above average for most indicators and sub-indicators, including per capita pharmaceutical expenditure, sector value growth and pensionable population. Consequently with this high score, Hong Kong is ranked fifth, above China, out of the 19 key Asia Pacific markets.

Full Report Details at
- http://www.fastmr.com/prod/900701_hong_kong_pharmaceuticals_healthcare_report_q1.aspx?afid=301

Key Trends And Developments

* In October 2014, DKSH signed an agreement with Roche, extending their partnership across several Asian markets including Hong Kong.
* In the same month, US-based Sorrento Therapeutics licensed out its Anti-PD-L1 antibody to China Onc ology Focus (an affiliate of Lee' s Pharmaceutical). Under the agreement, Lee's Pharma received exclusive rights to develop and commercialise the antibody for the greater Chinese market.
* In September 2014, local media, South China Morning Post, reported that only 80 out of more than 400 private sector doctors in Hong Kong joined a public-private partnership scheme that subsidises the treatment of some public-hospital patients at private clinics. The scheme, which aims to ease demand in the understaffed public sector, has been implemented in three districts: Wong Tai Sin, Kwun Tong and Tuen Mun. The project is expected to provide 30,000...

The Hong Kong Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Hong Kong Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Hong Kong pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Hong Kong to test other views - a key input for successful budgeting and strategic business planning in the Hong Kong pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Slovenia Pharmaceuticals & Healthcare Report Q1 2015
- Thailand Pharmaceuticals & Healthcare Report Q1 2015
- Kenya Pharmaceuticals & Healthcare Report Q1 2015
- Croatia Pharmaceuticals & Healthcare Report Q1 2015
- Singapore Pharmaceuticals & Healthcare Report Q4 2014